Flonoltinib Maleate (novel JAK inhibitor for myelofibrosis)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-03-04 — A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis: Trial-early: multicenter, open-label, positive-drug parallel-controlled phase trial enrolling ~105 intermediate/high-risk MF patients (2:1 experimental:active comparator), stratified by DIPSS; outcomes not yet reported in abstract. (novelty: 3)
Open questions
Related
Contributing findings
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
04-mar-2026
novelty 3
per-area 3
introduces